Clinical trial · Interventional
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer
NCT01031225CI-TRIAL-00015654completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA 9090 | Drug | Ganetespib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: STA 9090
Primary outcomes (1)
- measure
- Progression Free Survival rate
- timeFrame
- 16 weeks
Secondary outcomes (2)
- measure
- Objective Response Rate, Disease Control Rate, Progression Free Survival, Overall Survival
- timeFrame
- 18 months
- measure
- Safety and tolerability as measured by adverse event rates and laboratory evaluations
- timeFrame
- 16 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression * Availability of tissue for analysis * ECOG Performance Status 0 or 1 * Adequate organ function as defined in the protocol. * Must be at least 18 years old and able and willing to sign a written informed consent document Exclusion Criteria: * Poor venous access requiring an indwelling catheter for study drug administration * Women who are pregnant or lactating * Ventricular ejection fraction \< or = to 55% at baseline * Any uncontrolled intercurrent illness
References
Publications (0)
Data not yet available
No reference posted for this study.